核受体、炎症与肝脏疾病：胆汁淤积性和脂肪性肝病的新视角。
Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases.
机构信息
Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
出版信息
Clin Pharmacol Ther. 2010 Apr;87(4):473-8. doi: 10.1038/clpt.2010.2. Epub 2010 Mar 3.
Abstract
Members of the nuclear receptor (NR) superfamily of ligand-activated transcription factors are players of substantial relevance in the regulation of hepatic gene expression. NRs direct normal physiology and metabolism, adaptations to liver disease, and responses to inflammation and toxins.They also contribute to the regenerative response. In this review, we summarize currently available experimental and clinical data, focusing on the role of NRs in cholestasis and nonalcoholic fatty liver disease (NAFLD). We also highlight the potential of NRs as targets for safe and effective therapeutic interventions.
摘要
核受体（NR）超家族的配体激活转录因子成员在调节肝脏基因表达中具有重要意义。NR 直接参与正常生理和代谢、肝脏疾病的适应以及炎症和毒素的反应，它们也有助于再生反应。在这篇综述中，我们总结了目前可用的实验和临床数据，重点介绍了 NR 在胆汁淤积和非酒精性脂肪性肝病（NAFLD）中的作用。我们还强调了 NR 作为安全有效的治疗干预靶点的潜力。
相似文献
1
Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases.核受体、炎症与肝脏疾病：胆汁淤积性和脂肪性肝病的新视角。
Clin Pharmacol Ther. 2010 Apr;87(4):473-8. doi: 10.1038/clpt.2010.2. Epub 2010 Mar 3.
2
Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?核受体作为肝脏疾病的治疗靶点：我们做到了吗？
Annu Rev Pharmacol Toxicol. 2016;56:605-626. doi: 10.1146/annurev-pharmtox-010715-103209.
3
Novel therapeutic targets for cholestatic and fatty liver disease.胆汁淤积性和脂肪性肝病的新型治疗靶点。
Gut. 2022 Jan;71(1):194-209. doi: 10.1136/gutjnl-2021-324305. Epub 2021 Oct 6.
4
Nuclear receptors in acute and chronic cholestasis.急性和慢性胆汁淤积中的核受体
Dig Dis. 2015;33(3):357-66. doi: 10.1159/000371688. Epub 2015 May 27.
5
Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease.用于治疗非酒精性脂肪性肝病的核受体调节
Semin Liver Dis. 2016 Feb;36(1):69-86. doi: 10.1055/s-0036-1571296. Epub 2016 Feb 12.
6
Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile.核受体配体增强脂肪变性：一项具有特征性核受体表达谱的人肝细胞和肝癌细胞培养研究。
Chem Biol Interact. 2010 Mar 30;184(3):376-87. doi: 10.1016/j.cbi.2010.01.008. Epub 2010 Jan 15.
7
Nuclear receptors in liver disease.核受体与肝脏疾病。
Hepatology. 2011 Mar;53(3):1023-34. doi: 10.1002/hep.24148. Epub 2011 Feb 11.
8
Farnesoid X receptor modulators (2011 - 2014): a patent review.法尼酯X受体调节剂（2011 - 2014年）：专利综述
Expert Opin Ther Pat. 2015;25(8):885-96. doi: 10.1517/13543776.2015.1045413.
9
Nuclear receptors: mediators and modifiers of inflammation-induced cholestasis.核受体：炎症诱导性胆汁淤积的介质和调节因子
Front Biosci (Landmark Ed). 2009 Jan 1;14(7):2599-630. doi: 10.2741/3400.
10
Look who's talking: nuclear receptors in the liver and gastrointestinal tract.看看是谁在说话：肝脏和胃肠道中的核受体。
Cell Metab. 2008 Mar;7(3):195-9. doi: 10.1016/j.cmet.2008.02.006.
引用本文的文献
1
Future therapeutic perspectives in nonalcoholic fatty liver disease: a focus on nuclear receptors, a promising therapeutic target.非酒精性脂肪性肝病的未来治疗前景：聚焦核受体，一个有前景的治疗靶点。
Med Pharm Rep. 2024 Apr;97(2):111-119. doi: 10.15386/mpr-2628. Epub 2024 Apr 25.
2
Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease.非酒精性脂肪性肝病炎症机制的最新评估
Front Pharmacol. 2023 Mar 16;14:1081334. doi: 10.3389/fphar.2023.1081334. eCollection 2023.
3
Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology.通过重建肠道微生态改善非酒精性脂肪性肝病的草药疗法。
Chin Med. 2021 Jul 27;16(1):62. doi: 10.1186/s13020-021-00470-x.
4
Long Noncoding RNA lnc-HC Regulates PPARγ-Mediated Hepatic Lipid Metabolism through miR-130b-3p.长链非编码RNA lnc-HC通过miR-130b-3p调控PPARγ介导的肝脏脂质代谢。
Mol Ther Nucleic Acids. 2019 Dec 6;18:954-965. doi: 10.1016/j.omtn.2019.10.018. Epub 2019 Oct 25.
5
Exposure to 2,4-dichlorophenoxyacetic acid induced PPARβ-dependent disruption of glucose metabolism in HepG2 cells.接触 2,4-二氯苯氧乙酸诱导 HepG2 细胞中 PPARβ 依赖性葡萄糖代谢紊乱。
Environ Sci Pollut Res Int. 2018 Jun;25(17):17050-17057. doi: 10.1007/s11356-018-1921-6. Epub 2018 Apr 9.
6
Bile acid detoxifying enzymes limit susceptibility to liver fibrosis in female SHRSP5/Dmcr rats fed with a high-fat-cholesterol diet.胆汁酸解毒酶可降低高脂胆固醇饮食喂养的雌性SHRSP5/Dmcr大鼠发生肝纤维化的易感性。
PLoS One. 2018 Feb 13;13(2):e0192863. doi: 10.1371/journal.pone.0192863. eCollection 2018.
7
Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor.水飞蓟素通过激活法尼酯X受体改善与饮食诱导肥胖相关的代谢功能障碍。
Front Pharmacol. 2016 Sep 28;7:345. doi: 10.3389/fphar.2016.00345. eCollection 2016.
8
RNA-Seq reveals common and unique PXR- and CAR-target gene signatures in the mouse liver transcriptome.RNA测序揭示了小鼠肝脏转录组中常见和独特的孕烷X受体及组成型雄烷受体靶基因特征。
Biochim Biophys Acta. 2016 Sep;1859(9):1198-1217. doi: 10.1016/j.bbagrm.2016.04.010. Epub 2016 Apr 23.
9
Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?核受体作为肝脏疾病的治疗靶点：我们做到了吗？
Annu Rev Pharmacol Toxicol. 2016;56:605-626. doi: 10.1146/annurev-pharmtox-010715-103209.
10
Biological functions of thyroid hormone in placenta.甲状腺激素在胎盘中的生物学功能。
Int J Mol Sci. 2015 Feb 16;16(2):4161-79. doi: 10.3390/ijms16024161.
本文引用的文献
1
Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis.脂肪细胞凋亡：肥胖、胰岛素抵抗与肝脂肪变性之间的联系。
J Biol Chem. 2010 Jan 29;285(5):3428-38. doi: 10.1074/jbc.M109.074252. Epub 2009 Nov 24.
2
Xenobiotic-sensing nuclear receptors CAR and PXR as drug targets in cholestatic liver disease.细胞色素 P450 相关受体 CAR 和 PXR 作为胆汁淤积性肝病的药物靶点。
Curr Drug Targets. 2009 Nov;10(11):1156-1163. doi: 10.2174/138945009789735174.
3
Fatty liver and lipotoxicity.脂肪肝与脂毒性
Biochim Biophys Acta. 2010 Mar;1801(3):299-310. doi: 10.1016/j.bbalip.2009.10.007. Epub 2009 Oct 24.
4
Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease.核受体CAR的激活可改善糖尿病和脂肪肝疾病。
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18831-6. doi: 10.1073/pnas.0909731106. Epub 2009 Oct 22.
5
Review article: nuclear receptors and liver disease--current understanding and new therapeutic implications.综述文章：核受体与肝脏疾病——当前的认识与新的治疗意义。
Aliment Pharmacol Ther. 2009 Oct 15;30(8):816-25. doi: 10.1111/j.1365-2036.2009.04104.x. Epub 2008 Jul 23.
6
New molecular insights into the mechanisms of cholestasis.新型分子深入洞察胆汁淤积的发病机制。
J Hepatol. 2009 Sep;51(3):565-80. doi: 10.1016/j.jhep.2009.05.012. Epub 2009 May 28.
7
Adipokines in liver diseases.肝脏疾病中的脂肪因子
Hepatology. 2009 Sep;50(3):957-69. doi: 10.1002/hep.23046.
8
New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD).非酒精性脂肪性肝病（NAFLD）的新诊断和治疗方法。
Ann Med. 2009;41(4):265-78. doi: 10.1080/07853890802552437.
9
Nuclear receptors: mediators and modifiers of inflammation-induced cholestasis.核受体：炎症诱导性胆汁淤积的介质和调节因子
Front Biosci (Landmark Ed). 2009 Jan 1;14(7):2599-630. doi: 10.2741/3400.
10
The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.法尼醇X受体（FXR）作为非酒精性脂肪性肝炎的新靶点。
Diabetes Metab. 2008 Dec;34(6 Pt 2):685-91. doi: 10.1016/S1262-3636(08)74605-6.
Zotero 插件